NervGen Pharma Corp V.NGEN

Alternate Symbol(s): NGENF

Healthcare

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.

TSXV:NGEN - Post by User

NervGen Pharma Corp

<< Previous

Bullboard Posts

Next >>

Post by deepoil0808on Mar 14, 2024 4:32pm

174 Views

Post# 35933552

200 day moving average $ 2.13/share

Looks like we are heading towards the 200 day moving average of $2.13 per share. Pretty steep slope so far.

If it breaks this support, then it confirms that the trials may not be going as planned.

The fact that observers are able to physically see the progression in a patient, makes it difficult to kept results secret.

Hence plunge in stock is not very reassuring.

Good Luck,

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant